GSK Completes $2.2 Billion Acquisition of RAPT Therapeutics, Adding Key Allergy Asset

summarizeSummary

GSK plc announced the completion of its acquisition of RAPT Therapeutics for approximately $2.2 billion, gaining a Phase IIb asset for food allergies.

check_boxKey Events

• Acquisition Completed

  GSK plc has completed its previously announced acquisition of RAPT Therapeutics, a clinical-stage biopharmaceutical company.

• Key Asset Acquired

  The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody in Phase IIb clinical development for prophylactic protection against food allergens.

• Financial Consideration

  The total cash consideration for the acquisition amounts to approximately $2.2 billion, with an upfront investment of approximately $1.9 billion net of cash acquired.

• Strategic Rationale

  Ozureprubart is considered a promising asset that complements GSK's expanding Respiratory, Immunology & Inflammation pipeline, offering potential for less frequent dosing and improved patient outcomes in food allergy treatment.

auto_awesomeAnalysis

GSK has finalized its acquisition of RAPT Therapeutics, a strategic move to bolster its Respiratory, Immunology & Inflammation pipeline. The core asset acquired is ozureprubart, a promising long-acting anti-IgE monoclonal antibody in Phase IIb development for food allergies. This acquisition, valued at $2.2 billion, represents a significant investment for GSK, aiming to address a substantial unmet medical need in food allergy treatment with a potentially best-in-class therapy offering less frequent dosing. The completion of this deal solidifies GSK's commitment to expanding its presence in the allergy market and leveraging its commercial footprint.